Type of Study: Retrospective observational cohort study Population: New users of GLP-1 RAs (semaglutide, tirzepatide, liraglutide) with overweight or obesity (BMI 27), regardless of type 2 diabetes status
I do have patients on semaglutide, and some are noticing that their hair is thinner and more brittle and that the texture has changed while on the medication, says Anthony Rossi, MD, an assistant professor of dermatology at Weill Cornell Medical College
These medications are approved only for type 2 diabetes management and chronic weight management, and any use for RA would be considered off-label without supporting clinical evidence
At least one, Zepbound, already included a warning label for people with severe gastroparesis and severe gastrointestinal disease
Schematic of the triple-receptor mechanism: GLP-1 (teal), GIP (blue) and glucagon (amber)
If you are only on a GLP-1 agonist or taking it with metformin, routine monitoring may be less frequent, but your diabetes team will provide personalised advice based on your treatment plan
